The anti-inflammatory and haemodynamic effects of levosimendan on advanced heart failure patients: a meta-analysis of published studies
Objective Increasing evidence from randomized controlled trials shows the anti-inflammatory and haemodynamic effects of levosimendan in advanced heart failure (AdHF), however, conflicting results have been reported in some studies. The aim of this study was to estimate the anti-inflammatory and haem...
Saved in:
Published in | Journal of international medical research Vol. 51; no. 7; p. 3000605221148402 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London, England
SAGE Publications
01.07.2023
Sage Publications Ltd SAGE Publishing |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
Increasing evidence from randomized controlled trials shows the anti-inflammatory and haemodynamic effects of levosimendan in advanced heart failure (AdHF), however, conflicting results have been reported in some studies. The aim of this study was to estimate the anti-inflammatory and haemodynamic effects of levosimendan on AdHF (registration number: INPLASY202250097).
Methods
The MEDLINE, PubMed, ClinicalTrials.com and Cochrane Library databases were systematically searched for studies published in English up to April 2019. Data were extracted from applicable articles. Meta-analyses were performed to assess interleukin (IL)-6, cardiac index, pulmonary artery pressure (PAP) and New York Heart Association (NYHA) functional class efficacy outcomes, following PRISMA 2020 guidelines.
Results
A total of 11 studies were included (211 patients who received levosimendan and 193 controls). Meta-analyses showed that the levosimendan group displayed significantly reduced IL-6 (standardized mean difference [SMD] −1.05; 95% confidence interval [CI] −1.44, −0.66; I
2
= 50.9%), improved cardiac index (SMD 0.59; 95% CI 0.29, 0.88; I2 = 0.0%); reduced PAP (SMD −1.22; 95% CI −1.91, −0.53; I2 = 89.7%) and improved NYHA functional class (SMD −1.66; 95% CI −2.27, −1.04; I2 = 74.6%) versus controls.
Conclusions
Levosimendan infusion was beneficial in patients with AdHF, displayed by anti-inflammatory and improved haemodynamic effects, and improved NYHA functional class. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 These authors contributed equally to this work. |
ISSN: | 0300-0605 1473-2300 |
DOI: | 10.1177/03000605221148402 |